Clinical Trials Logo

Primary Immune Thrombocytopenia clinical trials

View clinical trials related to Primary Immune Thrombocytopenia.

Filter by:

NCT ID: NCT03771378 Recruiting - Clinical trials for Primary Immune Thrombocytopenia

Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

(ITP;rhTPO)
Start date: January 16, 2019
Phase: Phase 4
Study type: Interventional

Primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. In most cases, platelet count is negatively correlated with the severity of bleeding. Correcting low platelets is the main measure to prevent bleeding in patients with ITP. Both rhTPO and eltrombopag act on TPO receptors to increase platelets.Which one will have a better short-term (2 weeks) effect to improve platelets is the purpose of the investigator's research.